Page last updated: 2024-11-01

ondansetron and Carcinoid Tumor

ondansetron has been researched along with Carcinoid Tumor in 2 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Carcinoid Tumor: A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ishizuka, J1
Hsieh, AC1
Townsend, CM1
Thompson, JC1
Jacobsen, MB1

Other Studies

2 other studies available for ondansetron and Carcinoid Tumor

ArticleYear
Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells.
    Surgical oncology, 1993, Volume: 2, Issue:4

    Topics: Calcium; Carcinoid Tumor; Cell Division; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Hydro

1993
Ondansetron in carcinoid syndrome.
    Lancet (London, England), 1992, Jul-18, Volume: 340, Issue:8812

    Topics: Aged; Carcinoid Tumor; Humans; Imidazoles; Male; Ondansetron; Pancreatic Neoplasms; Serotonin Antago

1992